Investors focused on the Medical space have likely heard of Fibrocell Science , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Fibrocell Science is one of 844 individual stocks in the Medical sector. Collectively, these companies sit at #3 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. FCSC is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for FCSC's full-year earnings has moved 51.12% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, FCSC has moved about 24.67% on a year-to-date basis. In comparison, Medical companies have returned an average of 2.74%. This shows that Fibrocell Science is outperforming its peers so far this year.
Looking more specifically, FCSC belongs to the Medical - Biomedical and Genetics industry, a group that includes 352 individual stocks and currently sits at #80 in the Zacks Industry Rank. On average, stocks in this group have gained 1.22% this year, meaning that FCSC is performing better in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to FCSC as it looks to continue its solid performance.